Phase 2 Brentuximab Vedotin ADC, a CD30-targeted tubulin inhibitor.

This trial at the University of Miami evaluates the efficacy and safety of the abbreviated BrECADD regimen in patients with Stage 2B-4 Hodgkin Lymphoma. An exploratory objective is to assess circulating tumor DNA as a biomarker for minimal residual disease over a 24‑month period.